These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24849042)

  • 1. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.
    Xin KQ; Mizukami H; Urabe M; Toda Y; Shinoda K; Yoshida A; Oomura K; Kojima Y; Ichino M; Klinman D; Ozawa K; Okuda K
    J Virol; 2006 Dec; 80(24):11899-910. PubMed ID: 17005662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
    Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.
    Ling C; Wang Y; Feng YL; Zhang YN; Li J; Hu XR; Wang LN; Zhong MF; Zhai XF; Zolotukhin I; Srivastava A; Ling CQ
    J Integr Med; 2015 Sep; 13(5):341-6. PubMed ID: 26343106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders.
    Wang X; Klann PJ; Wiedtke E; Sano Y; Fischer N; Schiller L; Elfert A; Güttsches AK; Weyen U; Grimm D; Vorgerd M; Bayer W
    Front Immunol; 2024; 15():1450858. PubMed ID: 39399494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
    Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
    J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
    Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML
    Hum Gene Ther; 2006 Apr; 17(4):440-7. PubMed ID: 16610931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer.
    Sun L; Tu L; Gao G; Sun X; Duan J; Lu Y
    J Immunol Methods; 2013 Jan; 387(1-2):114-20. PubMed ID: 23063691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus.
    Andrzejewski S; Murali A; Ramlogan-Steel C; Edwards KP; Efron N; Steel JC; Layton CJ
    Gene Ther; 2019 Jun; 26(6):250-263. PubMed ID: 30962537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.
    Baatartsogt N; Kashiwakura Y; Hiramoto T; Hayakawa M; Kamoshita N; Ohmori T
    J Gene Med; 2023 Aug; 25(8):e3505. PubMed ID: 36972408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of AAV2.5 neutralizing antibodies in synovial fluid and serum of patients with osteoarthritis.
    Abdul TY; Hawse GP; Smith J; Sellon JL; Abdel MP; Wells JW; Coenen MJ; Evans CH; De La Vega RE
    Gene Ther; 2023 Aug; 30(7-8):587-591. PubMed ID: 35260797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.